Key facts
- This page summarizes Michael Celano's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2023, 19:16.
Michael Celano - 31 Jan 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)
- Form type
- 4
- Accepted by SEC
- 02 Feb 2023, 19:16:57 UTC
- Previous filing
- 19 Sep 2022
- Next filing
- 18 May 2023
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Jennifer Johansson, Attorney-in-fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Celano filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 02 Feb 2023.
Change
- Previous filing in this sequence was filed on 19 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LRMR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +76,000
- Change %
- +239%
- Price
- $0.000000
- Shares after
- 107,746
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LRMR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $4.94
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
Footnote F2
The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.